Xilio Therapeutics (XLO) Restructuring Costs (2024)

Xilio Therapeutics' (XLO) quarterly Restructuring Costs came in at -$41000.0 in Q3 2024, down 236.67% quarter-over-quarter from $30000.0 in Q2 2024.

Xilio Therapeutics (XLO) Restructuring Costs (2024) Analysis & Trends

Xilio Therapeutics has disclosed Restructuring Costs across 1 years of filings, most recently posting -$41000.0 for Q3 2024.

Restructuring Costs for Q3 2024 came in at -$41000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $937000.0 (changed N/A YoY), and the FY2024 annual result was $937000.0, changed N/A from the prior year.
Restructuring Costs came in at -$41000.0 for Q3 2024 at Xilio Therapeutics, down from $30000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $948000.0 in Q1 2024 to a low of -$41000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Xilio Therapeutics	144.35 Mn	-5.95 Mn	-

Download Data